NOX 14.3% 8.0¢ noxopharm limited

BMS woes continue

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market - The ASCO Post

    Opdivo was granted accelerated approval in 2018 for small cell lung cancer based on surrogate endpoints, but has now been withdrawn from the US market, having failed to achieve its primary endpoint of Overall Survival in confirmatory studies.

    This emphasises the urgent need that BMS and Merck have to find ways to make Opdivo and Keytruda work in more patients and in more forms of cancer.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.010(14.3%)
Mkt cap ! $23.37M
Open High Low Value Volume
7.0¢ 8.0¢ 7.0¢ $4.207K 56.02K

Buyers (Bids)

No. Vol. Price($)
1 118527 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 4999 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.